Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc.  (NYSE: ANRO). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company. The Company’s product pipeline includes ALTO-100, which at the time of the Company's February 2, 2024 IPO was in a Phase 2b clinical trial for the treatment of patients with major depressive disorder (“MDD”).

A recently filed federal securities fraud class action complaint alleges that Alto Neurosciences, Inc. (NYSE: ANRO), through certain of its officers, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) ALTO-100 was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto's business and/or financial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT YOU CAN DO NOW: If you purchased Alto Neuroscience, Inc. (NYSE: ANRO) shares on or near the Company’s February 2, 2024 IPO, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  If, alternatively, you purchased your shares between February 2, 2024, and October 22, 2024, you can participate in the class action.